Kintara Therapeutics Enhances REM-001 Study with Pembrolizumab Patients
Wednesday, 27 March 2024, 13:21
Kintara Therapeutics Expands REM-001 Study
Kintara Therapeutics has recently announced an expansion of the REM-001 study in metastatic breast cancer, aiming to enhance treatment options.
Optimizing Study Design
The inclusion of patients receiving pembrolizumab reflects a strategic move to refine the study design for Phase 3 trials.
This step potentially opens up new avenues for combined therapies to improve patient outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.